BCDA Stock Analysis: Buy, Sell, or Hold?
BCDA - BioCardia, Inc. Common Stock
$0.92
-0.11 (-11.07%)
▼
5d:
-0.43%
30d:
-15.96%
90d:
-28.44%
BUY
HIGH Confidence
Analysis Updated: Jun 5, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When BCDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BCDA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: BCDA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: BCDA is currently trading at $0.92, which is considered fair relative to its 30-day fair value range of $0.92 to $1.12.
Technical Outlook: Technically, BCDA is in a strong downtrend. Immediate support is located at $0.86, while resistance sits at $1.80. Short-term momentum is weak, with the stock down 11.1% recently.
Market Sentiment: BCDA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $15.50 (+1404.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BCDA is in a strong downtrend. Immediate support is located at $0.86, while resistance sits at $1.80. Short-term momentum is weak, with the stock down 11.1% recently.
Market Sentiment: BCDA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $15.50 (+1404.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.92 -
$1.12
Company Quality Score
58/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
76.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BEARISH: Downward momentum (-11.1%)
- BULLISH: Trading 1404.9% below Wall St target ($15.50)
Trading Range Analysis
30-Day Trading Range
$0.92 -
$1.12
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.86
Resistance Level
$1.80
Current Trend
Strong Downtrend
Technical data as of
Jun 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.84
Wall Street Target
$15.50
(+1404.9%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 08, 2026 11:41 AM ET
Data refreshes hourly during market hours. Next update: 12:41 PM
Data refreshes hourly during market hours. Next update: 12:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCDA showing a specific setup today?
Insider Activity (6 Months)
7
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Peter Altman
BUY
400 shares
2026-04-21
Peter Altman
BUY
600 shares
2026-04-20
Peter Altman
BUY
5000 shares
2026-02-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1023 | 67 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$295 | 53 HOLD |